PCM
ABCL icon

Prelude Capital Management’s AbCellera Biologics ABCL Stock Holding History

Prelude Capital Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,800
Closed -$183K – 1749
2021
Q4 		$183K Buy
12,800
+100
+0.8% +$1.52K ﹤0.01% 1588
2021
Q3 		$255K Buy
+12,700
New +$224K 0.01% 1224

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Prelude Capital Management's ABCL Position: Q1 2026 in Review

Prelude Capital Management sold out of AbCellera Biologics (ABCL) in Q1 2026, closing a stake of 109,000 shares — an estimated $373K sold.

Prelude Capital Management first reported a position in ABCL in Q2 2024 and held it in 3 quarters. The position peaked at $373K in Q4 2025. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Prelude Capital Management reported no remaining AbCellera Biologics position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 109,000 AbCellera Biologics shares in Q1 2026, an estimated $373K.
  • Prelude Capital Management first reported a position in AbCellera Biologics in Q2 2024 and held it in 3 quarters.
  • Prelude Capital Management's AbCellera Biologics position peaked at $373K in Q4 2025.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.